Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells

Min Seong Kim; Hyesoo Kim; Gabsang Lee

doi:10.1002/adhm.202303041

Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells

Adv Healthc Mater. 2024 Jan 25:e2303041. doi: 10.1002/adhm.202303041. Online ahead of print.

Authors

Min Seong Kim^{1

2}, Hyesoo Kim^{1

2}, Gabsang Lee^{1

2

3}

Affiliations

¹ Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
² Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
³ The Solomon Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.

PMID: 38269602
DOI: 10.1002/adhm.202303041

Abstract

Parkinson's disease (PD) is one of the most devastating neurological diseases; however, there is no effective cure yet. The availability of human induced pluripotent stem cells (iPSCs) provides unprecedented opportunities to understand the pathogenic mechanism and identification of new therapy for PD. Here a new model system of PD, including 2D human iPSC-derived midbrain dopaminergic (mDA) neurons, 3D iPSC-derived midbrain organoids (MOs) with cellular complexity, and more advanced microphysiological systems (MPS) with 3D organoids, is introduced. It is believed that successful integrations and applications of iPSC, organoid, and MPS technologies can bring new insight on PD's pathogenesis that will lead to more effective treatments for this debilitating disease.

Keywords: Parkinson's disease; induced pluripotent stem cells; microphysiological systems; midbrain organoids.

Publication types

Review

Grants and funding

R01NS093213/NS/NINDS NIH HHS/United States